LEXX · Lexaria Bioscience Corp.
Substantial doubt about the company's ability to continue as a going concern.
“The recurring losses and negative net cash flows raise substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed Jul 13, 2026
One customer — 100% of revenue (nine months ended May 31, 2026)
“In the nine months ended May 31, 2026, the Company recognized revenue of $20,000 on a consolidated basis. One customer accounted for 100% of that total.”
2 customers — 100% of revenue (nine months ended May 31, 2025)
“In the nine months ended May 31, 2025, the Company recognized revenue of $531,923 on a consolidated basis. Two customers accounted for 100% of that total.”
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Aug 3, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Aug 3, 2026.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LEXX
this stock
Lexaria Bioscience Corp.
|
$17.10M | — | +52.0% | — | 1.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.1% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +3.5% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.23B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Aug 3, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LEXX | +7.0% | +137.5% | — | — | — |
| SPY | +0.5% | +1.2% | +13.3% | +2.7% | +12.5% |
| vs SPY | +6.6% | +136.2% | — | — | — |